Characteristic
|
Total (N = 109)
|
G based (N = 43)
|
A based (N = 66)
|
P*
|
---|
N (%)
|
N (%)
|
N (%)
|
---|
Center
|
0.16
|
INT
|
78 (72)
|
34 (79)
|
44 (67)
|
IEO
|
31 (28)
|
9 (21)
|
22 (33)
|
Age
|
0.59
|
Median
|
50
|
49
|
52
|
IQR
|
43–57
|
43–56
|
44–59
|
Stage
|
0.59
|
IA
|
20 (19)
|
7 (17)
|
13 (21)
|
IB
|
83 (81)
|
35 (83)
|
48 (79)
|
NA
|
6
|
1
|
5
|
Mitotic index
|
0.37
|
Median
|
21
|
25
|
16
|
IQR
|
12–34
|
14–34
|
12–33
|
NA
|
55
|
16
|
39
|
Surgery
|
0.53
|
LPT
|
90 (88)
|
34 (85)
|
56 (90)
|
LPS
|
12 (12)
|
6 (15)
|
6 (10)
|
NA
|
7
|
3
|
4
|
Morcellation
|
0.04
|
No
|
52 (72)
|
15 (58)
|
37 (80)
|
Yes
|
20 (28)
|
11 (42)
|
9 (20)
|
NA
|
37
|
17
|
20
|
Oophorectomy
|
0.19
|
No
|
27 (27)
|
13 (34)
|
14 (22)
|
Yes
|
74 (73)
|
25 (66)
|
49 (78)
|
NA
|
8
|
5
|
3
|
RT
|
0.05
|
No
|
98 (90)
|
42 (98)
|
56 (85)
|
Yes
|
11 (10)
|
1 (2)
|
10 (15)
|
- *Chi-square test, Fisher exact test or Mann-Whitney U test as appropriate
- INT Fondazione IRCCS Istituto Nazionale dei Tumori of Milan, IEO European Institute of Oncology, IQR interquartile range, G gemcitabine, A anthracycline, RT radiotherapy